Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?

News
Article

Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.

Emerging research suggests significant agreement between photon-counting computed tomography (PCCT) and magnetic resonance imaging (MRI) with respect to hepatic fat fraction quantification.

In a new prospective study, recently published in Radiology, researchers compared contrast-enhanced PCCT fat quantification to MRI proton density fat fraction (PDFF) in 125 participants, liver biopsy in 27 participants, and controlled attenuation parameter (CAP) measurements derived from transient elastography in 26 participants. The 178-participsant cohort was comprised of people with known or suspected liver disease, according to the study.

The researchers found a 91 percent intraclass correlation coefficient (ICC) between PCCT and MRI PDFF for liver fat fraction assessment. They also noted a 92 percent ICC between the imaging modalities for participants without fibrosis and an 84 percent ICC for participants with fibrosis.

Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?

Here one can see regions of interest for liver fat fraction value measurements on photon-counting CT fat map (top row) along with MRI scans revealing corresponding proton density fat fraction measurements (middle row) and transient elastography-derived measurements of controlled attenuation measurements (bottom row). (Images courtesy of Radiology.)

“PCCT-based assessment of liver steatosis showed excellent agreement with the clinical reference standard for noninvasive assessment of liver fat fraction, MRI PDFF, without evidence of systematic deviation between the two modalities. Notably, even the presence of a fibrotic liver parenchymal structure did not appear to impact the accuracy of the PCCT measurement method,” wrote lead study author Tatjana Dell, M.D., who is affiliated with the Department of Diagnostic and Interventional Radiology and Quantitative Imaging Lab Bonn at the University Hospital Bonn in Bonn, Germany, and colleagues.

Employing a 4.8 percent threshold for PCCT discrimination of steatosis, the researchers pointed out that PCCT offered similar sensitivity (81 percent) to MRI PDFF (86 percent).

The study authors noted a number of benefits with PCCT in comparison to MRI in this patient population.

“PCCT offers potential advantages over MRI, including faster scan times and high patient acceptance. Additionally, breathing artifacts are encountered less frequently on PCCT scans than on MRI scans. Patients with pacemakers and other implants can undergo PCCT without concern,” said Dell and colleagues.

Three Key Takeaways

1. Strong agreement between PCCT and MRI PDFF. Photon-counting computed tomography (PCCT) demonstrated excellent correlation (91 percent intraclass correlation coefficient) with MRI proton density fat fraction (PDFF) in assessing liver fat fraction, making it a promising alternative for hepatic fat quantification.

2. Reliability in fibrotic livers. PCCT maintained high accuracy for fat quantification even in patients with liver fibrosis, showing an 84 percent ICC in this subgroup. This suggests its potential utility in broader clinical scenarios, including patients with chronic liver disease.

3. Advantages and limitations of PCCT. PCCT offers faster scan times, higher patient acceptance, and fewer breathing artifacts than MRI. However, it has lower specificity (71 percent vs. 83 percent for MRI), making it less suitable for primary steatosis screening but valuable for incidental detection in routine CT exams.

While PCCT’s lower specificity for steatosis in contrast to MRI (71 percent vs. 83 percent) curtails the use of PCCT for primary screening of steatosis, the researchers emphasized ancillary detection benefit during routine CT exams.

“The additional information could help clinicians identify patients with steatosis at an early stage, depending on risk stratification,” added Dell and colleagues.

(Editor’s note: For related content, see “New Study Identifies Key Computed Tomography Findings for Post-Op Recurrence of Pancreatic Cancer,” “Abdominal CT Study Shows 20 Percent Reduction in Iodine Contrast with Photon Counting CT” and “Can Photon-Counting CT Facilitate a Viable Alternative to MRI for Liver Fat Quantification in Patients with MASLD?”)

Beyond the inherent limitations of a single-center study, the researchers conceded a small number of participants in the cohort with advanced steatosis and that all PCCT exams were performed with a single scanner. They also noted the high proportion of fibrosis in the biopsy group may have affected the study results.

Recent Videos
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Radiology Study Finds Increasing Rates of Non-Physician Practitioner Image Interpretation in Office Settings
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Related Content
© 2025 MJH Life Sciences

All rights reserved.